



## Company Announcement

No. 2/2015

# Zealand announces a change to its Board of Directors

Copenhagen, 2 February 2015 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) announced today that Florian Reinaud, independent Board member and Chairman of the Remuneration Committee, will step down from the Board with effect as of today. This change is in line with Zealand’s previously communicated Board transition plans.

Florian Reinaud, who is partner at Innovation Capital, France has served on Zealand’s Board of Directors since 2010.

New Chairman of the Remuneration Committee will be Daniel J. Ellens.

Commenting on this Board change, **Daniel J. Ellens, Chairman of Zealand’s Board of Directors**, said: *“This announced board change is part of a natural maturation of Zealand. We thank Florian for his valuable contribution over the past five years and wish him well for the future.”*

\*\*\*

### For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer  
Tel: +45 51 67 61 28, email: [bmj@zealandpharma.com](mailto:bmj@zealandpharma.com)

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications  
Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)

### About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for Lyxumia® is planned for Q3 2015 and US/EU filings for LixiLan in Q4 2015.

Zealand proprietary pipeline includes danegaptide (prevention of Ischemic Reperfusion Injury) and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.

For further information: [www.zealandpharma.com](http://www.zealandpharma.com)

Follow us on Twitter @ZealandPharma